CASI Pharmaceuticals, Inc. (NASDAQ:CASI)

CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company’s products present antiangiogenic solutions to cancer, cardiovascular disease, and macular degeneration. CASI Pharmaceuticals Inc., formerly known as EntreMed, Inc., is headquartered in Rockville, Maryland.

CASI Pharmaceuticals, Inc. (NASDAQ:CASI)’s Financial Overview

CASI Pharmaceuticals, Inc. (NASDAQ) surged 0% yesterday to close its trading session at $4.28. The company has 1 year Price Target of $7. CASI Pharmaceuticals, Inc. has 52-Week high of $8.89 and 52-Week Low of $2.55. The stock touched its 52-Week High on 8.89 and 52-Week Low on 2.55. The stock traded with the volume of 0 shares yesterday. The firm shows the market capitalization of $361.66 Million.

CASI Pharmaceuticals, Inc. (NASDAQ) reported its last quarterly earnings on 6/29/2018 where the firm reported its Actual EPS of $-0.07/share against the analyst consensus estimate of $-0.07/share. The difference between the actual and expected EPS is $0 a share with a surprise factor of 0%.

The firm is trading with SMA20 of 12.37 Percent, SMA50 of 13.62 Percent and SMA200 of -24.68 percent. CASI Pharmaceuticals, Inc. has P/S value of 0 while its P/B value stands at 3.29. Similarly, the company has Return on Assets of -28.7 percent, Return on Equity of -30.7 percent and Return on Investment of 0 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 0 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 2 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 1 analysts offering 12-month price forecasts for CASI Pharmaceuticals Inc have a median target of 7.00, with a high estimate of 7.00 and a low estimate of 7.00. The median estimate represents a +63.55% increase from the last price of 4.28.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

NewLink Genetics Corporation (NASDAQ:NLNK)

NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa.

NewLink Genetics Corporation (NASDAQ:NLNK)’s Financial Outlook

The 3 analysts offering 12-month price forecasts for NewLink Genetics Corp have a median target of 5.00, with a high estimate of 5.00 and a low estimate of 4.00. The median estimate represents a +168.82% increase from the last price of 1.86.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, NewLink Genetics Corporation has a Consensus Recommendation of 3. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock surged 0% and closed its last trading session at $1.86. The company has the market capitalization of $72.13 Million. The stock has 52-week high of $10.41 and 52-Week low of $1.8. The firm touched its 52-Week high on 10.41 and 52-Week low on 1.80. The company has volume of 0 shares. The company has a total of 38.78 Million shares outstanding.

NewLink Genetics Corporation (NASDAQ) in the last quarter reported its actual EPS of $-0.2/share where the analyst estimated EPS was $-0.4/share. The difference between the actual and Estimated EPS is $0.2. This shows a surprise factor of 50 percent.

The company has YTD performance of -77.07 percent. Beta for NewLink Genetics Corporation stands at 1.41 while its ATR (average true range) is 0.15. The company has Weekly Volatility of 7.13%% and Monthly Volatility of 7.48%%.

NewLink Genetics Corporation has distance from 20-day Simple Moving Average (SMA20) of -5.08%, Distance from 50-Day Simple Moving Average of -11.61 percent and Distance from 200-Day Simple Moving Average of -55.45%.

The Company currently has ROA (Return on Assets) of -35.8 percent, Return on Equity (ROE) of -42.3 Percent and Return on Investment (ROI) of -47.6% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *